Definium Therapeutics reports Phase 3 topline success for LSD (DT120) in generalized anxiety disorder, following MDD progress. Here’s the clinical context and what DMV patients should watch.

Resilient resubmits MDMA-assisted therapy to FDA, Definium reports positive oral LSD Phase 3 data in GAD, and Canada funds a C$24M cannabis–brain health consortium.